We have substantial programmes of work which aim to generate and evaluate the next generation of novel therapies which we hope will transform patient care. These include the development of novel antibody based therapies and small molecule inhibitors. We are also focussed on developing new interventional and surgical techniques which we hope will improve patient outcomes. This collective programme of work is supported by our clinical trials team which allow us to objectively assess whether the new treatments are superior to historical best practice. We welcome the support of our clients in this programmes of work and if you would like more information please do not hesitate to ask your vet for further details. This article was published on 2024-09-02